EUVIMEDEUVIMED entdecken
MetaanalyseVergleichsstudie

Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs

Yongjin Han, Ying Zhou, Jing Na, Fuhang Li, Yingxian Sun

American Journal of Hypertension · 15.11.2023 · 36 (12) · 643-650

DOI: 10.1093/ajh/hpad075 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift American Journal of Hypertension, online erschienen am 19.08.2023. Verfasst von Yongjin Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang 110001, China. Hauptthemen laut MEDLINE: Blood Pressure, Hypertension, Imidazoles, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Sacubitril/valsartan (LCZ696) is a widely used drug for hypertension in Asia, popular for its efficacy and safety. However, there has been no comprehensive literature review comparing it with olmesartan. This meta-analysis compared the antihypertensive and adverse effects of sacubitril/valsartan and olmesartan. METHODS We conducted a comprehensive search of Pubmed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov databases to identify eligible randomized controlled trials (RCTs). The data were then analyzed and processed using Revman 5.4 and Stata SE14 software. RESULTS Six RCTs with 4,127 patients were identified, showing that LCZ696 had better blood pressure control than olmesartan; mean sitting systolic and diastolic blood pressure, sitting pulse pressure, 24-hour ambulatory systolic blood pressure, and 24-hour ambulatory diastolic blood pressure were significantly decreased with LCZ696 compared with olmesartan. No significant difference between LCZ696 and olmesartan was observed in the occurrence of the majority of adverse events, with a decreased probability of headache in patients with sacubitril/valsartan compared with olmesartan. The subgroup analysis showed treatment with 400 mg/d LCZ696 was better than olmesartan in reducing serious adverse events. CONCLUSIONS Sacubitril/valsartan was better than olmesartan in controlling blood pressure in patients with hypertension, with relatively higher safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PressureHypertensionImidazolesRandomized Controlled Trials as TopicTetrazolesValsartanHumansAminobutyratesAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsAntihypertensive AgentsBiphenyl CompoundsDrug CombinationsTreatment Outcome

Stichwörter der Autor:innen

blood pressurehypertensionmeta-analysisolmesartansacubitril/valsartan

Substanzen

AminobutyratesAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsAntihypertensive AgentsBiphenyl CompoundsDrug CombinationsImidazolesolmesartansacubitril and valsartan sodium hydrate drug combinationTetrazoles

Autor:innen und Institutionen

  • Department of Cardiology, First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang 110001, China.

Zitieren

APA

Han, Y., Zhou, Y., Na, J., Li, F., & Sun, Y. (2023). Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs. American Journal of Hypertension, 36(12), 643-650. https://doi.org/10.1093/ajh/hpad075

Vancouver

Han Y, Zhou Y, Na J, Li F, Sun Y. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs. American Journal of Hypertension. 2023;36(12):643-650. doi:10.1093/ajh/hpad075

BibTeX
@article{Han2023,
  author = {Han, Yongjin and Zhou, Ying and Na, Jing and Li, Fuhang and Sun, Yingxian},
  title = {Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs},
  journal = {American Journal of Hypertension},
  year = {2023},
  volume = {36},
  number = {12},
  pages = {643--650},
  doi = {10.1093/ajh/hpad075}
}
Kostenlos starten →